• 1
    O’Dwyer ME, Druker BJ. The role of the tyrosine kinase inhibitor STI571 in the treatment of cancer. Curr Cancer Drug Targets 2001; 1: 4957.
  • 2
    Yamamoto M, Kurosu T, Kakihana K, Mizuchi D, Miura O. The two major imatinib resistance mutations E255K and T315I enhance the activity of BCR/ABL fusion kinase. Biochem Biophys Res Commun 2004; 319: 12725.
  • 3
    Chomel JC, Sorel N, Bonnet ML et al. Quantitative monitoring of the T315I mutation in patients with chronic myeloid leukemia (CML). Leuk Res 2009; 33: 5515.
  • 4
    Wagh V, Chile S, Monahar S et al. NPB001-05 inhibits Bcr-Abl kinase leading to apoptosis of imatinib-resistant cells. Front Biosci (Elite Ed) 2011; 3: 127388.
  • 5
    Wagh V, Mishra P, Thakkar A et al. Antitumor activity of NPB001-05, an orally active inhibitor of Bcr-Abl tyrosine kinase. Front Biosci (Elite Ed) 2011; 3: 134964.
  • 6
    Jeng JH, Chang MC, Hahn LJ. Role of areca nut in betel quid-associated chemical carcinogenesis: current awareness and future perspectives. Oral Oncol 2001; 37: 47792.
  • 7
    Amonkar AJ, Nagabhushan M, D’Souza AV, Bhide SV. Hydroxychavicol: a new phenolic antimutagen from betel leaf. Food Chem Toxicol 1986; 24: 13214.
  • 8
    Nagabhushan M, Amonkar AJ, Nair UJ, D’Souza AV, Bhide SV. Hydroxychavicol: a new anti-nitrosating phenolic compound from betel leaf. Mutagenesis 1989; 4: 2004.
  • 9
    Chang MC, Uang BJ, Wu HL, Lee JJ, Hahn LJ, Jeng JH. Inducing the cell cycle arrest and apoptosis of oral KB carcinoma cells by hydroxychavicol: roles of glutathione and reactive oxygen species. Br J Pharmacol 2002; 135: 61930.
  • 10
    Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov 2009; 8: 57991.
  • 11
    Rakshit S, Bagchi J, Mandal L et al. N-acetyl cysteine enhances imatinib-induced apoptosis of Bcr-Abl+ cells by endothelial nitric oxide synthase-mediated production of nitric oxide. Apoptosis 2009; 14: 298308.
  • 12
    Rakshit S, Mandal L, Pal BC et al. Involvement of ROS in chlorogenic acid-induced apoptosis of Bcr-Abl+ CML cells. Biochem Pharmacol 2010; 80: 166275.
  • 13
    Wang L, Jin Y, Arnoldussen YJ et al. STAMP1 is both a proliferative and an antiapoptotic factor in prostate cancer. Cancer Res 2010; 70: 581828.
  • 14
    Ishihara Y, Shimamoto N. Involvement of endonuclease G in nucleosomal DNA fragmentation under sustained endogenous oxidative stress. J Biol Chem 2006; 281: 672633.
  • 15
    Kondo-Nakamura M, Shintani-Ishida K, Uemura K, Yoshida K. Brief exposure to carbon monoxide preconditions cardiomyogenic cells against apoptosis in ischemia-reperfusion. Biochem Biophys Res Commun 2010; 393: 44954.
  • 16
    Merle PL, Sabourault C, Richier S, Allemand D, Furla P. Catalase characterization and implication in bleaching of a symbiotic sea anemone. Free Radic Biol Med 2007; 42: 23646.
  • 17
    Lozzio CB, Lozzio BB. Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood 1975; 45: 32134.
  • 18
    Kishi K. A new leukemia cell line with Philadelphia chromosome characterized as basophil precursors. Leuk Res 1985; 9: 38190.
  • 19
    Kubonishi I, Miyoshi I. Establishment of a Ph1 chromosome-positive cell line from chronic myelogenous leukemia in blast crisis. Int J Cell Cloning 1983; 1: 10517.
  • 20
    Shah NP, Nicoll JM, Nagar B et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002; 2: 11725.
  • 21
    Burgess MR, Skaggs BJ, Shah NP, Lee FY, Sawyers CL. Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Proc Natl Acad Sci USA 2005; 102: 3395400.
  • 22
    Chen J, Higby R, Tian D et al. Toxicological analysis of low-nicotine and nicotine-free cigarettes. Toxicology 2008; 249: 194203.
  • 23
    Trachootham D, Zhou Y, Zhang H et al. Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell 2006; 10: 24152.
  • 24
    Bandyopadhyay G, Biswas T, Roy KC et al. Chlorogenic acid inhibits Bcr-Abl tyrosine kinase and triggers p38 mitogen-activated protein kinase-dependent apoptosis in chronic myelogenous leukemic cells. Blood 2004; 104: 251422.
  • 25
    Ublacker GA, Johnson JA, Siegel FL, Mulcahy RT. Influence of glutathione S-transferases on cellular glutathione determination by flow cytometry using monochlorobimane. Cancer Res 1991; 51: 17838.
  • 26
    Riedl SJ, Shi Y. Molecular mechanisms of caspase regulation during apoptosis. Nat Rev Mol Cell Biol 2004; 5: 897907.
  • 27
    Saunders JA, Rogers LC, Klomsiri C, Poole LB, Daniel LW. Reactive oxygen species mediate lysophosphatidic acid induced signaling in ovarian cancer cells. Free Radic Biol Med 2010; 49: 205867.
  • 28
    Impellizzeri D, Esposito E, Mazzon E et al. Effect of apocynin, a NADPH oxidase inhibitor, on acute lung inflammation. Biochem Pharmacol 2011; 81: 63648.
  • 29
    Kang C, O’Moore KM, Dickman JR, Ji LL. Exercise activation of muscle peroxisome proliferator-activated receptor-gamma coactivator-1alpha signaling is redox sensitive. Free Radic Biol Med 2009; 47: 1394400.
  • 30
    Maeda H, Akaike T, Yoshida M, Sato K, Noguchi Y. A new nitric oxide scavenger, imidazolineoxyl N-oxide derivative, and its effects in pathophysiology and microbiology. Curr Top Microbiol Immunol 1995; 196: 3750.
  • 31
    Corbett JA, McDaniel ML. The Use of Aminoguanidine, a Selective iNOS Inhibitor, to Evaluate the Role of Nitric Oxide in the Development of Autoimmune Diabetes. Methods 1996; 10: 2130.
  • 32
    Belik J, Jankov RP, Pan J, Tanswell AK. Peroxynitrite inhibits relaxation and induces pulmonary artery muscle contraction in the newborn rat. Free Radic Biol Med 2004; 37: 138492.
  • 33
    Stricklett PK, Hughes AK, Kohan DE. Endothelin-1 stimulates NO production and inhibits cAMP accumulation in rat inner medullary collecting duct through independent pathways. Am J Physiol Renal Physiol 2006; 290: F13159.
  • 34
    Blatt NB, Boitano AE, Lyssiotis CA, Opipari AW Jr, Glick GD. Bz-423 superoxide signals apoptosis via selective activation of JNK, Bak, and Bax. Free Radic Biol Med 2008; 45: 123242.
  • 35
    Liu J, Lin A. Role of JNK activation in apoptosis: a double-edged sword. Cell Res 2005; 15: 3642.
  • 36
    Xu H, Dhanasekaran DN, Lee CM, Reddy EP. Regulation of neurite outgrowth by interactions between the scaffolding protein, JNK-associated leucine zipper protein, and neuronal growth-associated protein superior cervical ganglia clone 10. J Biol Chem 2010; 285: 354853.
  • 37
    Ramirez P, DiPersio JF. Therapy options in imatinib failures. Oncologist 2008; 13: 42434.
  • 38
    Boschelli F, Arndt K, Gambacorti-Passerini C. Bosutinib: a review of preclinical studies in chronic myelogenous leukaemia. Eur J Cancer 2010; 46: 17819.
  • 39
    Santos FP, Kantarjian H, Cortes J, Quintas-Cardama A. Bafetinib, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor for the potential treatment of leukemia. Curr Opin Investig Drugs 2010; 11: 145065.
  • 40
    Walz C, Sattler M. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML). Crit Rev Oncol Hematol 2006; 57: 14564.
  • 41
    An X, Tiwari AK, Sun Y, Ding PR, Ashby CR Jr, Chen ZS. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review. Leuk Res 2010; 34: 125568.
  • 42
    Carew JS, Nawrocki ST, Kahue CN et al. Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance. Blood 2007; 110: 31322.
  • 43
    Chandra J, Tracy J, Loegering D et al. Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance. Blood 2006; 107: 25016.
  • 44
    Raj L, Ide T, Gurkar AU et al. Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature 2011; 475: 2314.
  • 45
    Nakamura T, Lipton SA. Cell death: protein misfolding and neurodegenerative diseases. Apoptosis 2009; 14: 45568.
  • 46
    Levonen AL, Laakso J, Vaskonen T, Mervaala E, Karppanen H, Lapatto R. Down-regulation of renal glutathione synthesis by systemic nitric oxide synthesis inhibition in spontaneously hypertensive rats. Biochem Pharmacol 2000; 59: 4413.